Kalibr8 is the Azure governance, FinOps, and CloudOps platform built specifically for Managed Service Providers (MSPs), Cloud Solution Providers (CSPs), and indirect CSPs. As Azure environments scale across tenants, subscriptions, and services, MSPs face increasing pressure to manage cost, maintain control, and continuously demonstrate value to customers — all while protecting margin. Kalibr8 brings governance, cost management, and operational automation together in a single multi-tenant platform designed for how MSPs actually work. With Kalibr8, MSPs can: Gain real-time visibility across every customer tenant Enforce governance through automated policies and controls Eliminate billing complexity with automated reconciliation Identify and execute cost optimisation opportunities at scale Track and protect margin across subscriptions and services Surface usage insights that drive upsell and growth opportunities Unlike traditional cloud cost tools built for single enterprises, Kalibr8 is purpose-built for multi-tenant MSP environments, CSP billing models, and distributor ecosystems. The result: Greater control, stronger margins, and more scalable Azure practices.
| Website | https://kalibr8.io/ |
| Employees | 12 (7 on RocketReach) |
| Founded | 2020 |
| Phone | +353 87 766 6077 |
| Industry | Technology, Information and Internet |
| Keywords | Cloud Optimization, Finops, Cloud Cost Management, Cloud Cost Optimization, Cloud Cost Control, Cloud Spend Optimization, Cloud Financial Management, Cloud Analytics, Cloud Automation, Cloud Cost Visibility, Cloud Resource Optimization, Cloud Cost Allocation, Cloud Cost Forecasting, Cloud Efficiency, Cloud Governance, Cloud Monitoring |
| Competitors | Qualtrics, Momentive.ai, Typeform, UserTesting, Case Closed Leads, Microsoft, Google, ProProfs, Zoho, Key Survey +32 more (view full list) |
Looking for a particular Kalibr8™ employee's phone or email?
Ben McGahon is the Co-Founder and CEO at kalibr8 - Multi-Tenant Finops for Azure MSPs of Kalibr8™.
7 people are employed at Kalibr8™.